JBIO - Aerovate Therapeutics, Inc.
25.21
-0.170 -0.674%
Share volume: 683,877
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$25.38
-0.17
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-13-2024 | 08-12-2024 | 11-12-2024 | 03-27-2025 | 04-25-2025 | 11-14-2025 | 03-06-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 24.618 M | 26.165 M | 17.410 M | 6.403 M | 3.387 M | 27.401 M | 54.976 M | |
| Selling general and admin | 4.538 M | 4.917 M | 7.082 M | 4.872 M | 3.387 M | 5.391 M | 6.412 M | |
| Research and development | 20.080 M | 21.248 M | 10.328 M | 1.531 M | 0.000 | 22.010 M | 48.564 M | |
| Total expenses | 24.618 M | 26.165 M | 17.410 M | 6.403 M | 3.387 M | 27.401 M | 54.976 M | |
| 6.28% | -33.46% | -63.22% | -47.10% | 709.01% | 100.64% | |||
| Operating income | -24.618 M | -26.165 M | -17.410 M | -6.403 M | -3.387 M | -27.401 M | -54.976 M | |
| Ebit | -24.621 M | -26.171 M | -17.410 M | -6.403 M | -3.387 M | -27.366 M | -54.976 M | |
| Pretax income | -23.186 M | -24.775 M | -16.237 M | -5.375 M | -2.518 M | -25.112 M | -67.588 M | |
| 6.85% | -34.46% | -66.90% | -53.15% | 897.30% | 169.15% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -23.186 M | -24.775 M | -16.237 M | -5.430 M | -2.518 M | -25.175 M | -67.583 M | |
| -6.85% | 34.46% | 66.56% | 53.63% | -899.80% | -168.45% |